PF-Atlas › Clinical Trials › NCT02055456
Nandrolone Decanoate in the Treatment of Telomeropathies
Nandrolone Decanoate · Phase 1
Registry ID
NCT02055456
Phase
Phase 1
Status
Completed
Drug / intervention
Nandrolone Decanoate
Sponsor
University of Sao Paulo
Start
2014-02-01
Enrollment
20
Locations
1
About this trial
Decrease in blood cell counts due to deficient bone marrow function, called bone marrow failure, as well as some lung diseases, called idiopathic pulmonary fibrosis, can be caused by genetic defects in telomere biology genes, eventually causing telomere erosion. These disorders are collectively termed "telomeropathies". There is evidence that male hormones may improve blood cell counts in marrow failure, and these hormones are able to stimulate telomerase function in hematopoietic cells in vitro. We propose this study to the use of male hormone in patients with aplastic anemia and pulmonary fibrosis associated with defects in telomeres.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT02055456 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.